PepGen EBITDA Growth & History (PEPG)
PepGen's calculated EBITDA was −$92.2M for fiscal 2025.
View full PepGen company overviewPepGen annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$92.2M | $4.0M | — |
| 2024 | 2024-12-31 | −$96.2M | −$12.7M | — |
| 2023 | 2023-12-31 | −$83.6M | −$15.8M | — |
| 2022 | 2022-12-31 | −$67.8M | −$40.9M | — |
| 2021 | 2021-12-31 | −$26.9M | — | — |
PepGen quarterly ebitda
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$18.6M | $5.0M | — |
| Q1 2026 | 2026-03-31 | −$18.6M | $12.3M | — |
| Q4 2025 | 2025-12-31 | −$19.3M | $4.7M | — |
| Q3 2025 | 2025-09-30 | −$18.4M | $4.4M | — |
| Q2 2025 | 2025-06-30 | −$23.6M | $6.4M | — |
| Q1 2025 | 2025-03-31 | −$30.9M | −$11.5M | — |
| Q4 2024 | 2024-12-31 | −$24.0M | −$3.6M | — |
| Q3 2024 | 2024-09-30 | −$22.8M | $1.7M | — |
| Q2 2024 | 2024-06-30 | −$30.0M | −$9.2M | — |
| Q1 2024 | 2024-03-31 | −$19.4M | −$1.6M | — |
| Q4 2023 | 2023-12-31 | −$20.4M | −$3.4M | — |
| Q3 2023 | 2023-09-30 | −$24.5M | −$5.0M | — |
| Q2 2023 | 2023-06-30 | −$20.8M | −$3.3M | — |
| Q1 2023 | 2023-03-31 | −$17.8M | −$4.0M | — |
| Q4 2022 | 2022-12-31 | −$17.0M | −$9.8M | — |
| Q3 2022 | 2022-09-30 | −$19.5M | −$11.5M | — |
| Q2 2022 | 2022-06-30 | −$17.5M | −$12.4M | — |
| Q1 2022 | 2022-03-31 | −$13.8M | −$7.2M | — |
| Q4 2021 | 2021-12-31 | −$7.3M | — | — |
| Q3 2021 | 2021-09-30 | −$8.0M | — | — |
| Q2 2021 | 2021-06-30 | −$5.1M | — | — |
| Q1 2021 | 2021-03-31 | −$6.6M | — | — |
PepGen ebitda trends
Between the periods ended 2021-12-31 and 2025-12-31, PepGen's ebitda decreased from −$26.9M to −$92.2M, a change of −$65.3M. The latest reported quarter, Q2 2026, shows −$18.6M.
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review PepGen source filings ↗Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...